Hypercalcemia Treatment Market

Hypercalcemia Treatment Market

Global hypercalcemia treatment market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Hypercalcemia is a condition in which the calcium level in the blood is above normal. Too much calcium in the blood can weaken the bones, create kidney stones and interfere with heart and brain work. Hypercalcemia is usually a result of overactive parathyroid glands. These four tiny glands are situated in the neck, near the thyroid gland. Other causes of hypercalcemia include cancer, certain other medical disorders, some medications and taking too much of calcium and vitamin D supplements.

If the hypercalcemia is mild, monitor the bones and kidneys over time to be sure they remain healthy. For more severe hypercalcemia, might recommend medications or treatment of the underlying disease, including surgery. If the hypercalcemia is due to an overactive parathyroid gland, will most likely recommend surgery to have the overactive parathyroid gland(s) removed. If the hypercalcemia is due to cancer, may suggest bisphosphonates, such as pamidronate and zoledronic acid or denosumab (XGEVA), a bone-strengthening medication, for people with cancer-caused hypercalcemia who do not respond to bisphosphonates.

Market Dynamics: Drivers

Rising adoption of novel therapeutics

The rising adoption of novel therapeutics is expected to drive the market over the forecast period. Ongoing research and development efforts in the pharmaceutical and biotechnology sectors contribute to the discovery of novel therapeutic agents for hypercalcemia. New drugs with improved efficacy and safety profiles are likely to be adopted more readily in clinical practice. The increasing FDA approvals for novel therapeutics are also expected to increase the adoption of these therapeutics.

For instance, on October 01, 2020, Dr Reddy’s Laboratories launched Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the US Food and Drug Administration (USFDA). Cinacalcet tablet is a positive modulator of the calcium-sensing receptor indicated for hypercalcemia in adult patients with parathyroid carcinoma (PC) and severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

In addition, advances in understanding the molecular and cellular mechanisms underlying hypercalcemia allow for the development of targeted therapies. Drugs designed to specifically address the underlying causes of hypercalcemia, such as those targeting parathyroid hormone or bone resorption pathways, may offer more precise and effective treatment options, which increases the adoption of these novel therapeutics.

Further, the increasing prevalence of hypercalcemia, rising FDA approvals for novel therapies, increasing clinical trials to develop more advanced therapies, increasing awareness about the condition and rising advancements in the development of novel therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and side effects associated with the drugs and surgery, the high cost of the surgery, availability of limited treatment options and unmet needs are the factors expected to hamper the market.

Segment Analysis

The global hypercalcemia treatment market is segmented based on treatment type, route of administration, end-user and region.

The calcimimetics segment accounted for approximately 54.4% of the hypercalcemia treatment market share

The calcimimetics segment is expected to hold the largest market share over the forecast period. Calcimimetics is commonly used for the treatment of hypercalcemia, particularly in cases related to primary hyperparathyroidism. These medications work by mimicking the action of calcium on the calcium-sensing receptors in the parathyroid gland, thereby reducing the secretion of parathyroid hormone (PTH). By inhibiting PTH release, calcimimetics help to regulate calcium levels in the blood.

For instance, on November 22, 2023, Kyowa Kirin Co., Ltd. launched ORKEDIA TABLETS 4mg (generic name: evocalcet). ORKEDIA TABLETS is an oral calcimimetics agent that suppresses parathyroid hormone (PTH) secretion by acting on the calcium receptors on parathyroid gland cells. The drug is approved in Japan for the treatment of secondary hyperparathyroidism in patients undergoing maintenance dialysis, hypercalcemia in patients with parathyroid carcinoma and hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy or who experience recurrent primary hyperparathyroidism.

In addition, its low dosage, ORKEDIA TABLETS 1mg and ORKEDIA TABLETS 2mg have helped many patients in Japan since their launch. With this higher dose, ORKEDIA TABLETS 4mg, it is expected to lead to a reduction in the burden of medication for patients and an improvement in treatment satisfaction.

Further, calcimimetics like cinacalcet are used to manage hypercalcemia in individuals with primary hyperparathyroidism. This condition is characterized by excessive secretion of PTH by the parathyroid glands, leading to elevated calcium levels in the blood. Calcimimetics act by modulating the activity of the calcium-sensing receptors on the parathyroid gland, leading to a decrease in PTH secretion and subsequent reduction in blood calcium levels.

Geographical Analysis

North America accounted for approximately 42.4% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing demand for hypercalcemia therapeutics. North America especially the United States is known as a hub for its strong presence of major players such as pharmaceutical companies which is expected to launch more advanced therapeutics for better treatment.

In addition, the higher prevalence of hypercalcemia contributes to a larger patient pool requiring better treatment, this increasing demand for hypercalcemia therapeutics is also helps to drive the market in the region. For instance, according to the National Institute of Health, the Estimated annual prevalence of hypercalcemia in the US was 71744 cases, respectively. HCM is estimated to have affected 2.8% and 2.0% of cancer patients.

Competitive Landscape

The major global players in the hypercalcemia treatment market include Novartis AG, Amgen Inc., Kyowa Kirin Co., Ltd., Aetna Inc., SOLITAIRE PHARMACIA PVT. LTD., Midas Pharma GmbH, Steris Healthcare Pvt. Ltd., Viatris Inc., Amolyt Pharma and Crinetics Pharmaceuticals, Inc. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global hypercalcemia treatment market. Many research and development efforts were redirected towards addressing the challenges posed by COVID-19. This shift in priorities might have impacted ongoing research on hypercalcemia treatment and the development of new therapeutic options. Clinical trials for new hypercalcemia treatments may have experienced delays due to lockdowns, restrictions on patient movements and challenges in conducting research during the pandemic. In addition, the pandemic disrupted the supply chain of the therapeutics globally.

Market Segmentation

By Treatment Type
• Calcitonin (Miacalcin)
• Calcimimetics
• Bisphosphonates
• Denosumab (Prolia, Xgeva)
• Glucocorticoids (Steroids)
• IV Fluids and Diuretics
• Surgery
• Others

By Route of Administration
• Intravenous
• Oral
• Others

By End-User
• Hospitals
• Specialty Clinics
• Academic and Research Institutes
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report?
• To visualize the global hypercalcemia treatment market segmentation based on treatment type, route of administration, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of hypercalcemia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hypercalcemia treatment market report would provide approximately 69 tables, 72 figures, and 187 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies